QuintilesIMS Partners for Oncology Insights

Newly merged health data giant QuintilesIMS is collaborating with a number of global pharmaceuticals firms to develop better insights into how cancer treatments are used in a real-world setting across key European markets.

Initial partners are Bristol-Myers Squibb; Eli Lilly and Company; Merck KGaA, Darmstadt, Germany; and Pfizer.

The data firm, which was formed from a $17.6bn Merger in May this year and has around 50,000 employees, says there are currently 'major information gaps and inconsistencies in knowledge about the real-world use of oncology products across Europe' - with treatment use information typically based on historical data. The new deal will improve understanding of how oncology products are actually used, for which types of patients, with what sequences and combinations of therapies, and in which indications - thus helping to improve patient care. QuintilesIMS says 'substantial steps' have been taken to respect individual privacy under the new system.

The service should help healthcare providers and governments with their healthcare resource management and planning, as well as aiding the development of new drugs.

According to the WHO, cancer causes more than 1.7 million deaths each year in Europe - second only to cardiovascular disease - and three million new cases are reported each year.

Web site: www.quintilesims.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• IMS Health Inc
• All news